June 9, 2022. Our Chairman Shi Yuanyuan and Chief Scientist Wang Jianxun led the company team to Shenzhen Hospital of Hong Kong University for learning and exchange with Director Wang Jun of Hematology Department. Director Wang Jun introduced in detail the clinical treatment effect and treatment plan of CAR-T medicine, as well as the physical and mental conditions of patients in the treatment process; Chairman Shi Yuanyuan and Professor Wang Jianxun introduced the advantages of retrovirus in CAR-T R&D and production and the technical details of CAR-T drugs from R&D to clinical stage. The two sides discussed the development of cell therapy industry and the difficulties of clinical treatment, hoping to promote the application and development of cell therapy in tumor treatment from initial research and development, clinical trials, industrial production, patient care and other aspects. Both sides reached a consensus on future oriented cooperation in clinical research of cell therapy.2022年6月9日。我司董事長(zhǎng)史淵源，首席科學(xué)家王建勛帶領(lǐng)公司團(tuán)隊(duì)前往香港大學(xué)深圳醫(yī)院與血液科王鈞主任進(jìn)行學(xué)習(xí)交流。王均主任詳細(xì)介紹了CAR-T藥物在臨床上的治療效果、治療方案以及病人在治療過程中的身體和精神狀況；史淵源董事長(zhǎng)和王建勛教授介紹了逆轉(zhuǎn)錄病毒在CAR-T研發(fā)生產(chǎn)上的優(yōu)勢(shì)以及CAR-T藥物從研發(fā)到臨床階段的技術(shù)細(xì)節(jié)。雙方探討了細(xì)胞治療行業(yè)發(fā)展和臨床治療的難點(diǎn)，希望從初期研發(fā)、臨床試驗(yàn)、工業(yè)化生產(chǎn)，病人護(hù)理關(guān)懷等各方面著手促進(jìn)細(xì)胞療法在腫瘤治療上的運(yùn)用與發(fā)展。雙方達(dá)成面向未來的在細(xì)胞治療臨床研究方面的合作共識(shí)。